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Pregnancy Following Sequential Bromocriptine Therapy in a 
Hyperprolactinemic Subject 
Malachi J. McKenna, MD,* M. Saeed-uz-Zafar, MD,^  and Raymond C. Mellinger, MD' 
Regular menses were maintained in a 26-year-old woman with a prolactinoma by sequential 
bromocriptine therapy given for either five or 14 days ofthe menstrual cycle. She conceived promptly 
when desired. (Henry FordHosp MedJ 1987:35:192-3) 
Prolactin-secreting pituitary neoplasms, a common cause of menstrual irregularity and infertility, usually require 
therapeutic intervention. Except for some adenomas which may 
require surgery to reduce mass effect, administration of bro-
mocriptine is generally considered the preferred method of man-
agement. Menses retum and conception can be readily achieved 
in about 80% of treated subjects. However, medical treatment is 
not curative, and continuous administration is usually needed to 
maintain normal ovarian function. We report the successful use 
of sequential bromocriptine, administered prior to ovulation, in 
maintaining normal menstrual cycles and in making conception 
achievable in a patient with a prolactinoma. 
Case Report 
A 26-year-old woman sought evaluation of oligomenorrhea and re-
duced libido which had been present for over two years. On examina-
tion, visual fields were intact to confrontation, and no hirsutism was 
present. Semm prolactin levels were consistently elevated between 298 
and 379 ng/mL. She was euthyroid. Computed tomography of the sella 
turcica suggested a right-sided pituitary neoplasm. Bromocriptine was 
given, with the dosage gradually increasing to 2.5 mg twice daily. Her 
semm prolactin level fell to 22 ng/mL in one month. After two regular 
menstrual periods, the patient became pregnant, and bromocriptine was 
discontinued. Serial Goldmann fields remained normal during her 
pregnancy. A healthy baby was delivered at 38 weeks of gestation. Ten 
weeks postpartum, her serum prolactin level was 520 ng/dL, and bro-
mocriptine was resumed at a dose of 2.5 mg twice daily for six months. 
After six months of therapy, a trial of sequential bromocriptine ad-
ministration was initiated to determine whether continuous control of 
hyperprolactinemia was necessary for preservation of cyclic ovarian 
function. The patient took 2.5 mg of bromocriptine twice daily from 
day 1 to day 14 of the menstrual cycle for 11 cycles and then took the 
same dose from day 1 to day 5 for two cycles. During the last cycle of 
therapy the patient discontinued contraception and consequent concep-
tion led to a full-term delivery of a second, healthy child. 
Serum prolactin levels, measured by radioimmunoassay (Abbot Lab-
oratories, North Chicago, IL), all were within the reference range (< 25 
ng/mL) immediately following a course of therapy and all were elevated 
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when tested during the weeks without treatment, ie, 110, UO, 140, and 
160 ng/mL. Serum estradiol-17B, measured by radioimmunoassay of 
an extract (Radioassay Systems Laboratories, Carson, CA), and serum 
progesterone, measured by a commercial laboratory (Metric Medical 
Labs, Southfield, Ml), were both evaluated in the luteal phase of four 
different cycles. Semm estradiol-178 levels were 130, 170, 210, and 
260 pg/mL (reference range: 50 to 150 pg/mL), and resfwctive serum 
progesterone levels were 9.0, 2.3, 10.9, and 15.4 ng/mL (reference 
range: 2.5 to 28.1 ng/mL). 
Discussion 
Over the past ten years, growing appreciation of the benign 
nature of microprolactinomas has led to conservative principles 
of management. In the past, transsphenoidal adenomectomy has 
often been recommended because of the fear of rapid tumor 
expansion, especially during pregnancy. The present trendis 
to provide symptomatic relief and to restore fertility by phar-
macologic means. Restoration and maintenance of normal me"' 
strual function indicate adequate estrogen production, whict 
bromocriptine can provide. However, infertility, galactorrhea, 
and menstrual irregularity usually recur following discontinua-
tion of bromocriptine. 
Although it was demonstrated ten years ago that sequel' 
rial bromocriptine therapy given during the follicular an 
periovulatory phase could induce ovulation and even result m 
pregnancy (1,2), such treatment is not routine. There is son" 
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jvidence that the length of the menstrual cycle is prolonged 
if bromocriptine is not administered at the beginning of the cycle 
,2) However, the present case suggests that normalization of 
rolactin during the first five days can permit ovulation and 
thereby conception. One presumptive advantage of sequential 
therapythat the fetus is not exposed to medication during the 
(.fitical days immediately following conception. Although ex-
tensive experience has failed to show any teratogenetic effects, 
it is preferable to avoid drugs during pregnancy. 
fhe mechanisms by which prolactin interferes with ovulation 
3iid menstrual functions are not entirely understood. However, 
disturbed ovarian function clearly results from abnormalities in 
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the secretion of pituitary gonadotrophins. Our observation sug-
gests that hyperprolactinemia may interfere with follicular re-
cruitment rather than impair follicular maturation, ovulation, or 
corpus luteum function. 
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